{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:28:18Z","timestamp":1787225298991,"version":"build-2736575974"},"reference-count":47,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Sci.","Medical Sciences"],"abstract":"<jats:p>Background: Biological treatment of psoriasis has revolutionized the therapy of this disease, in most cases enabling complete remission of skin lesions. Methods: This study aimed to analyze real-world evidence from 165 patients (mean age 38.1 \u00b1 5.66) treated with 11 biological drugs at our Dermatology Department. Results: Skin lesion severity, expressed by Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA), improved significantly throughout the treatment, along with the quality of life, expressed by Dermatology Life Quality Index (DLQI) (all p &lt; 0.0001). We observed a statistically significantly higher reduction in skin lesion severity and life quality improvement with IL-23 and IL-17 inhibitors compared to TNF\u03b1 inhibitors (both p &lt; 0.0001). Secondary loss of response was observed in 26.7% of patients treated with anti-TNF agents, compared to 15.0% in the anti-IL-23 group and 8.3% in the anti-IL-17 group (\u03c72 test, p = 0.0683). Patients who had been treated in the past with biologics had significantly higher PASI and BSA at week 16 of therapy compared to those who were bio-na\u00efve. A positive correlation was demonstrated between PASI at 16 weeks and BMI (R = 0.15; p = 0.0396). There was no correlation between the duration of psoriasis, sex, or age of patients when introducing biologics and PASI at any of the timepoints (p &gt; 0.05). The most frequent side effects were infections, occurring mainly in patients on anti-TNF\u03b1 agents and bimekizumab. Conclusions: IL-17 and IL-23 inhibitors demonstrated superior efficacy compared to TNF\u03b1 inhibitors, with higher rates of complete skin clearance and a lower tendency toward loss of response. The worst efficacy and the highest rate of loss of response were observed in case of adalimumab. These findings support the increasing role of IL-17 and IL-23 inhibitors as preferred therapeutic options in psoriasis. Previous biologic exposure and higher BMI seem to be associated with poorer therapeutic outcomes. Overall, biological treatment is an effective, rapid, and safe therapeutic option.<\/jats:p>","DOI":"10.3390\/medsci14040502","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:55:18Z","timestamp":1787223318000},"page":"502","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Evaluation of the Clinical Effectiveness and Safety of Biologic Therapies in Psoriasis\u2013Real-World Evidence up to 64 Weeks of Therapy"],"prefix":"10.3390","volume":"14","author":[{"given":"Patrycja","family":"Lemiesz","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6870-1167","authenticated-orcid":false,"given":"Julia","family":"Nowowiejska-Purpurowicz","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8688-4171","authenticated-orcid":false,"given":"Tomasz W.","family":"Kaminski","sequence":"additional","affiliation":[{"name":"Department of Medicine, Pittsburgh Heart, Lung and Blood Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA 15260, USA"},{"name":"Thrombosis and Hemostasis Program, Versiti Blood Research Institute and Blood Center of Wisconsin, Milwaukee, WI 53226, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5923-910X","authenticated-orcid":false,"given":"Iwona","family":"Flisiak","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St., 15-540 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/1346-8138.15840","article-title":"Psoriasis: Comorbidities","volume":"48","author":"Yamazaki","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40257-024-00857-0","article-title":"Managing the patient with psoriasis and metabolic comorbidities","volume":"25","author":"Bellinato","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/jdv.18044","article-title":"Psoriasis and metabolic syndrome: Implications for the management and treatment of psoriasis","volume":"36","author":"Wu","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ad.2022.07.021","article-title":"Quality of life and body region affected by psoriasis: A systematic review","volume":"114","author":"Nabieva","year":"2023","journal-title":"Actas Dermosifiliogr."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Nowowiejska, J., Baran, A., Hermanowicz, J.M., Sieklucka, B., Krahel, J.A., Kiluk, P., Pawlak, D., and Flisiak, I. (2022). Fatty acid-binding protein 7 (FABP-7), glutamic acid and neurofilament light chain (NFL) as potential markers of neurodegenerative disorders in psoriatic patients\u2014A pilot study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092430"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/1203475420903682","article-title":"A brief history of psoriasis management in Canada","volume":"24","author":"Maliyar","year":"2020","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s40261-024-01368-w","article-title":"Efficacy and safety of topical roflumilast for the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials","volume":"44","author":"Mesquita","year":"2024","journal-title":"Clin. Drug Investig."},{"key":"ref_8","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: A network meta-analysis","volume":"7","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2611461","DOI":"10.1080\/07853890.2025.2611461","article-title":"The molecular mechanism of the adverse effects of biological and small molecular drugs in the therapy of inflammatory skin diseases\u2014Psoriasis and atopic dermatitis","volume":"58","author":"Lemiesz","year":"2026","journal-title":"Ann. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Nowowiejska, J., Baran, A., Hermanowicz, J.M., Pryczynicz, A., Sieklucka, B., Pawlak, D., and Flisiak, I. (2023). Gasdermin D (GSDMD) Is Upregulated in Psoriatic Skin\u2014A New Potential Link in the Pathogenesis of Psoriasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713047"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/ITT.S282466","article-title":"All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD\u2014A Clinical Perspective","volume":"9","author":"Jefremow","year":"2020","journal-title":"ImmunoTargets Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus Secukinumab in Plaque Psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Jan, Z., El Assadi, F., Velayutham, D., Mifsud, B., and Jithesh, P.V. (2025). Pharmacogenomics of TNF inhibitors. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1521794"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Gargiulo, L., Ibba, L., Malagoli, P., Balato, A., Bardazzi, F., Burlando, M., Carrera, C.G., Damiani, G., Dapavo, P., and Dini, V. (2024). Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: A retrospective multicenter real-world experience on 5932 treatment courses\u2014IL PSO (Italian landscape psoriasis). Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1341708"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000488586","article-title":"Effectiveness end points in real-world studies on biological therapies in psoriasis: Systematic review with focus on drug survival","volume":"234","author":"Costanzo","year":"2018","journal-title":"Dermatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/1346-8138.13157","article-title":"Effect of a family history of psoriasis and age on comorbidities and quality of life in patients with moderate to severe psoriasis: Results from the ARIZONA study","volume":"43","author":"Sulleiro","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40257-025-00918-y","article-title":"The impact of family history on clinical presentation and biologic treatment response in patients with psoriasis: A multicenter prospective cohort study","volume":"26","author":"Jiang","year":"2025","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/j.1365-2133.2007.07906.x","article-title":"Family history of psoriasis and age at disease onset in Italian patients with psoriasis","volume":"156","author":"Altobelli","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Sch\u00e4kel, K. (2019). Psoriasis pathogenesis and treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1573715","DOI":"10.3389\/fimmu.2025.1573715","article-title":"Targeting nail psoriasis: IL-17A inhibitors demonstrate site-specific superiority over IL-23 inhibitor in a 24-week dermoscopy-guided real-world cohort","volume":"16","author":"Yan","year":"2025","journal-title":"Front. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s40257-023-00786-4","article-title":"Efficacy and safety of nail psoriasis targeted therapies: A systematic review","volume":"24","author":"Hwang","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2263108","DOI":"10.1080\/09546634.2023.2263108","article-title":"Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24\u201328 and 48\u201352 weeks","volume":"34","author":"Egeberg","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/09546634.2020.1770167","article-title":"Biologics and small molecules in patients with scalp psoriasis: A systematic review","volume":"33","author":"Alsenaid","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e14857","DOI":"10.1111\/dth.14857","article-title":"Therapeutic update of biologics and small molecules for scalp psoriasis: A systematic review","volume":"34","author":"Camela","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Blauvelt","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/bjd.15666","article-title":"Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study","volume":"177","author":"Reich","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): Results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaad.2024.12.016","article-title":"The association between obesity and efficacy of psoriasis therapies: An expert consensus panel","volume":"92","author":"Burshtein","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Di Giulio, S., Falcidia, C., Foggi, G., Bianco, M., Gargiulo, L., Valenti, M., Costanzo, A., Narcisi, A., and Ibba, L. (2025). Predictors of super-responder status to anti-IL-23 therapies in moderate-to-severe plaque psoriasis: A real-world monocenter study. J. Clin. Med., 14.","DOI":"10.3390\/jcm14186371"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamadermatol.2024.1677","article-title":"Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis: A Meta-analysis","volume":"160","author":"Hjort","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mennella, A., and Frasca, L. (2025). The phenomenon of anti-drug antibodies in psoriasis: Mechanisms, clinical impact, and therapeutic strategies. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26199616"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Loft, N., Altintas, S., Al-Sofi, R., Isufi, D., Zachariae, C., Kaur-Knudsen, D., Nielsen, C.H., and Skov, L. (2025). The Association Between Genetics and Response to Treatment with Biologics in Patients with Psoriasis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26188998"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Caputo, V., Strafella, C., Cosio, T., Lanna, C., Campione, E., Novelli, G., Giardina, E., and Cascella, R. (2021). Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis. Genes, 12.","DOI":"10.3390\/genes12091398"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study","volume":"37","author":"Reich","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/ajd.14254","article-title":"Drug survival of biologics in psoriasis: An Australian multicentre retrospective study","volume":"65","author":"Ting","year":"2024","journal-title":"Australas. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/bjd\/ljaf017","article-title":"Age and biologic survival in patients with moderate-to-severe psoriasis: A cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)","volume":"192","author":"Alabas","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/09546634.2016.1230173","article-title":"Eczema as an adverse effect of anti-TNF\u03b1 therapy in psoriasis and other Th1-mediated diseases: A review","volume":"28","author":"Nakamura","year":"2017","journal-title":"J. Dermatol. Treat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1177\/12034754221111111","article-title":"Review and practical guidance on managing fungal infections in patients with psoriasis receiving anti-IL-17 therapies","volume":"26","author":"Yeung","year":"2022","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.3899\/jrheum.201532","article-title":"Pooled safety results through 1 year of 2 phase III trials of guselkumab in patients with psoriatic arthritis","volume":"48","author":"Rahman","year":"2021","journal-title":"J. Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"100067","DOI":"10.1016\/j.crimmu.2023.100067","article-title":"Characteristics and sources of tissue-resident memory T cells in psoriasis relapse","volume":"4","author":"Dong","year":"2023","journal-title":"Curr. Res. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab","volume":"141","author":"Mehta","year":"2021","journal-title":"J. Investig. Dermatol."}],"container-title":["Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/4\/502\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:05:34Z","timestamp":1787223934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3271\/14\/4\/502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["medsci14040502"],"URL":"https:\/\/doi.org\/10.3390\/medsci14040502","relation":{},"ISSN":["2076-3271"],"issn-type":[{"value":"2076-3271","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]}}}